Mirabella Financial Services LLP Has $2.19 Million Holdings in argenex SE $ARGX

Mirabella Financial Services LLP grew its position in argenex SE (NASDAQ:ARGX) by 144.5% in the third quarter, Holdings Channel reports. The fund owned 2,976 shares of the company’s stock after acquiring an additional 1,759 shares during the quarter. Mirabella Financial Services LLP’s holdings in argenex were worth $2,191,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Ameriflex Group Inc. bought a new stake in argenex during the 3rd quarter worth $32,000. Bessemer Group Inc. raised its position in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of argenex during the third quarter valued at about $50,000. Rossby Financial LCC boosted its stake in shares of argenex by 115.2% during the third quarter. Rossby Financial LCC now owns 71 shares of the company’s stock valued at $54,000 after purchasing an additional 38 shares in the last quarter. Finally, TD Private Client Wealth LLC grew its holdings in shares of argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock worth $63,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

argenex stock opened at $703.30 on Tuesday. The stock’s 50 day moving average is $802.05 and its 200 day moving average is $817.48. argenex SE has a one year low of $510.05 and a one year high of $934.62. The firm has a market cap of $43.52 billion, a P/E ratio of 36.03, a P/E/G ratio of 1.16 and a beta of 0.38.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. Equities analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on ARGX shares. HC Wainwright upped their price objective on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Morgan Stanley boosted their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. JPMorgan Chase & Co. upped their price target on shares of argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Stifel Nicolaus raised their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.